A Mass Balance Study of [14C]ABSK021

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

December 13, 2023

Primary Completion Date

May 30, 2024

Study Completion Date

July 30, 2024

Conditions
Healthy Subjects
Interventions
DRUG

Pimicotinib(ABSK021)

A standard meal should be given to the subjects in the evening before dosing. Then, the subjects should fast for at least 10 hours. Water is not prohibited overnight. The next morning, the subjects should administer study drug in fasted state with warm water. The total volume of warm water and suspension is approximately 240 mL. Water is prohibited from 1 hour before dosing to 1 hour after dosing. No food is allowed within 4 hours after dosing. During the study, subjects will receive standardized meals at approximately the same time each day.

Trial Locations (1)

215000

The First Affiliated Hospital of SOOCHOW UNIVERSITY, Suzhou

Sponsors
All Listed Sponsors
lead

Abbisko Therapeutics Co, Ltd

INDUSTRY